| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.067 | 0.08 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.1 | 0.08 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.08 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.057 | 0.08 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | 0.066 | 0.08 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.08 |
| mRNA | piperlongumine:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.065 | 0.08 |
| mRNA | JW-7-52-1 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.08 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | 0.061 | 0.08 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.077 | 0.08 |